Biden’s Vaccine Donation Plan Emphasizes American Production, Not IP Waivers
President announces ‘new effort’ to work with pharmaceutical companies, other nations to increase supply. Details remain in short supply, but Biden says plan will increase domestic production capacity to prepare ‘the next crises.’
You may also be interested in...
Three groups representing the domestic and multinational research-based pharma industry in Japan present a unified position as they call for policy changes they see as providing the right environment for investment, innovation and a sustainable healthcare system.
Drug manufacturers still have a variety of ways to limit the impact of the Biden administration’s historic decision. Whether the huge political loss for industry translates into more than just headline-risk or faster global COVID vaccination remains to be seen. It's also not clear whether it’s an ominous sign for other industry battles in the US, including the drug pricing debate.
BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.